New research out of Harvard University strongly suggests that infection with the Epstein-Barr virus (EBV) is the leading cause of a debilitating disease of the brain and CNS – multiple sclerosis.   

Researchers globally produce hundreds of thousands of studies annually. It can be difficult to know if at some time in the future they will be the foundation for a disease cure or a technology such as CRISPR that revolutionizes medicine. But many are exciting for what they point to or how they spike the imagination. BioSpace reviews 10 of the more compelling research stories of 2021.

A study out of the University of Gothenberg found that good control of blood sugar is important for decreasing the risk of cancer in obesity and type 2 diabetes.

A team of Yale researchers found a key to unlocking the deadly mystery of brain aneurysms in adults.  

CMI Media Group has issued the “2021/2022 Media Vitals™ What Healthcare Consumers Want and Need from Life Sciences Manufacturers” report. Media Vitals research, which is conducted by CMI Media Group, is an annual barometer of the wants and needs of the company’s key consumer audiences.

Japan’s Takeda Pharmaceutical announced deals with two biotech companies, Seattle-based Immusoft and San Diego’s Poseida Therapeutics.

Young men could be at higher risk of contracting Covid-19 than previously recognized, researchers suggested, citing computer models.

One of the more cynical attacks on our industry goes something like this: “Taxpayers fund medical research through research grants, so they should get the benefits of any discoveries, not the greedy pharma companies.” I’m sure you’ve heard it. Politicians and pundits of all stripes love to reinforce the idea that pharma is gorging at the public trough – that all we do is gobble up federal grants as seed money for our outrageously priced nostrums. 

Finding more information about your personal health or the health of your family has never been more meaningful than over the past year. For many individuals, patients and consumers, the need to address myriad questions and seek out additional areas of interest has become a quest. But in an age when information is ubiquitous and public health is top of mind, a new study on health fluency indicates that the road to such insight is now paved with multiple lanes and involves more than the traditional health care organizations and companies relied on before.

Placebo response is one of the most significant challenges faced by drug developers who are investigating new pain medications. According to a review of published chronic neuropathic pain trials, placebo responses have increased in magnitude over time, making it even more difficult to definitively demonstrate treatment advantage. Research has also shown that up to 60 percent of study participants may experience placebo-related analgesic responses and that these responses may be persistent.